U.S. Abbott Unit Sues Sun To Bar Zemplar Generic Before Patent Expires
This article was originally published in PharmAsia News
Executive Summary
Abbot Laboratories subsidiary AbbVie is has sued Sun Pharmaceuticals to block U.S. marketing of its generic version of Zemplar (paricalcitol) for treating late-stage kidney disease.